0
$0.00
Cagrilintide

BATCH

PURITY

99% HPLC

  • CAS #:
  • 1415456-99-3
  • Formula:
  • C194H312N54O59S2
  • M.W.:
  • 4409 g/mol

Cagrilintide

Appetite ReshapingGlucose RegulationMetabolic EfficiencyWeight Loss

$220.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $220.00
2 - 4 $198.00
5 - 9 $187.00
10 - 14 $176.00
15 - 19 $165.00
20 + $154.00
Only the lyophilized product is provided. All supplies sold separately. For research use only.

Summary

Cagrilintide, a synthetic analogue of the natural hormone amylin, has shown promising potential in supporting weight loss and improving metabolic health. Clinical studies highlight its effectiveness in obesity management, with weight reduction of 6–11% of body weight achieved over 20 weeks when administered weekly (1, 2). When combined with semaglutide, the results are even more significant, demonstrating weight loss of up to 17% of body weight in the same period (1, 2). By targeting appetite regulation, glucose control, and energy balance, cagrilintide may represent an important step forward in managing obesity, type 2 diabetes, and related metabolic conditions (1, 3).

Batch Testing Reports

Cagrilintide

Cagrilintide

Description & Pharmacodynamics

Cagrilintide works by enhancing the body’s natural mechanisms for appetite control and energy regulation. As an analogue of amylin, it is designed to be more stable and long-acting, overcoming some of the limitations of the natural peptide (6, 7). Its mechanisms include:

  • Promoting Satiety: Activates receptors in the brain to enhance feelings of fullness, helping to naturally reduce food intake (1, 2).
  • Slowing Gastric Emptying: Extends digestion time, leading to more gradual nutrient absorption and improved blood sugar stability (1, 3).
  • Regulating Glucagon: Decreases glucagon secretion, which helps prevent excessive conversion of glucose into fat (3).
  • Enhanced Stability: Modifications to its structure improve its efficacy and half-life, allowing for once-weekly dosing (6).

These effects, in combination, support weight management and glycemic control in patients with obesity and type 2 diabetes (1, 3).

Research Insights

Obesity
  • Weight Loss Outcomes: Clinical trials demonstrate weight loss of 6–11% over 20 weeks with cagrilintide alone (1). When paired with semaglutide, weight loss can reach up to 17% of body weight during the same timeframe (1, 2).
  • Caloric Regulation: By enhancing satiety and reducing hunger, cagrilintide supports sustainable dietary adjustments (1).
Type 2 Diabetes
  • Improved Glycemic Control: Cagrilintide reduces hemoglobin A1C by up to 2.2%, improves insulin sensitivity, and decreases glucagon levels, contributing to better glucose management (3).
  • Pancreatic Benefits: Its actions help protect and preserve pancreatic function, minimizing strain on insulin production (3).
Cardiovascular Health
  • Risk Reduction: Through weight reduction and improved metabolic parameters, cagrilintide may help reduce cardiovascular risks commonly associated with obesity and type 2 diabetes (1, 3).
Liver Health
  • Liver Support: Preliminary research suggests benefits in conditions like non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease due to its role in reducing adiposity and improving metabolic regulation (5).
Neurodegenerative Conditions
  • Potential for Cognitive Health: Amylin-related peptides, including cagrilintide, are being explored for their potential role in addressing Alzheimer’s disease and other neurodegenerative conditions, although this remains an area of emerging research (4).

Structure

  • Sequence: [Details of amino acid sequence]
  • Molecular Formula: C₂₂₈H₃₆₆N₆₄O₆₆S₂
  • Molecular Weight: ~5,074 Da
  • PubChem CID: 171397054

Citations for Cagrilintide

Obesity
  1. Lau, D. C. W., et al. Once-weekly cagrilintide for weight management in people with overweight and obesity.Lancet, 2021. DOI: 10.1016/S0140-6736(21)01751-7.
  2. Enebo, L. B., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide.Lancet, 2021. DOI: 10.1016/S0140-6736(21)00845-X.
Type 2 Diabetes
  1. Frias, J. P., et al. Efficacy and safety of cagrilintide with semaglutide in type 2 diabetes. Lancet, 2023. DOI: 10.1016/S0140-6736(23)01163-7.
Neurodegenerative Research
  1. Qiu, W. Q., et al. Association between amylin and amyloid-β peptides. PLoS One, 2014. DOI: 10.1371/journal.pone.0088063.
Liver Disease
  1. Bailey, C. J., et al. Peptide-based therapies for obesity and type 2 diabetes. Peptides, 2024. DOI: 10.1016/j.peptides.2024.171149.
General References
  1. Kruse, T., et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J. Med. Chem., 2021. DOI: 10.1021/acs.jmedchem.1c00565.
  2. Pittner, R. A., et al. Molecular physiology of amylin. Journal of Cellular Biochemistry, 1994. DOI: 10.1002/jcb.240550004.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings

AOD-9604

Fat Burner

$88.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Lean Muscle Mass Peptide Stack

$804.96

View
Buy

Semaglutide / Cagrilintide

2ND GENERATION "OZEMPIC"

$220.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Tirzepatide

"MOUNJARO" PEPTIDE

From $250.00

View
Buy This product has multiple variants. The options may be chosen on the product page